The diagnostic value of EMA expression in the renal parenchyma tumors

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 3 SUPPL., 2012, Pages 1019-1025

  Alexa, Aurora ^a   Baderca, Flavia ^a   Lighezan, Rodica ^a   Zǎhoi, Delia Elena ^a   Izvernariu, D ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

EMA; Immunohistochemistry; Renal parenchyma tumors

Indexed keywords

EID: 84865719494     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kusafuka K, Itoh H, Sugiyama C, Nakajima T, Low-grade salivary duct carcinoma of the parotid gland: report of a case with immunohistochemical analysis, Med Mol Morphol, 2010, 43(3):178-184.
2. Turányi E, Dezsö K, Csomor J, Schaff Z, Paku S, Nagy P, Immunohistochemical classification of ductular reactions in human liver, Histopathology, 2010, 57(4):607-614.
3. Vered M, Allon I, Buchner A, Dayan D, Stromal myofibro-blasts accompany modifications in the epithelial phenotype of tongue dysplastic and malignant lesions, Cancer Micro-environ, 2009, 2(1):49-57.
4. Duncan TJ, Watson NFS, Al-Attar AH, Scholefield JH, Durrant LG, The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer, World J Surg Oncol, 2007, 5:31.
5. Shalom-Barak T, Nicholas JM, Wang Y, Zhang X, Ong ES, Young TH, Gendler SJ, Evans RM, Barak Y, Peroxisome proliferator-activated receptor gamma controls Muc1 transcription in trophoblasts, Mol Cell Biol, 2004, 24(24):10661-10669.
6. Sim SJ, Ro JY, Ordonez NG, Park YW, Kee KH, Ayala AG, Metastatic renal cell carcinoma to the bladder: a clinico- pathologic and immunohistochemical study, Mod Pathol, 1999, 12(4):351-355.
7. Kim MK, Kim S, Immunohistochemical profile of common epithelial neoplasms arising in the kidney, Appl Immunohistochem Mol Morphol, 2002, 10(4):322-328.
8. Lapinski JE, Chen L, Zhou M, Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: utility of immuno- histochemical markers, Appl Immunohistochem Mol Morphol, 2010, 18(5):414-421.
9. st edition, Churchill Livingstone, 2002, 452-485.
10. Liu LN, Chen GY, Wang P, Zhang CH, Huang SF, Papillary renal cell carcinoma: clinico-pathologic studies of 33 cases, Zhonghua Zhong Liu Za Zhi, 2005, 27(2):102-105.
11. Liu J, Fanning CV, Can renal oncocytomas be distinguished from renal cell carcinoma on fine-needle aspiration speci- mens? A study of conventional smears in conjunction with ancillary studies, Cancer, 2001, 93(6):390-397.
12. Taki A, Nakatani Y, Misugi K, Yao M, Nagashima Y, Chromophobe renal cell carcinoma: an immunohisto- chemical study of 21 Japanese cases, Mod Pathol, 1999, 12(3):310-317.
13. Bazille C, Allory Y, Molinié V, Vieillefond A, Cochand-Priollet B, Cussenot O, Callard P, Sibony M, Immunohisto- chemical characterisation of the main histologic subtypes of epithelial renal tumours on tissue-microarrays. Study of 310 cases, Ann Pathol, 2004, 24(5):395-406.
14. Kumar S, Carr T, Marsden HB, Calabuig-Crespo MC, Study of childhood renal tumours using antisera to fibronectin, laminin, and epithelial membrane antigen, J Clin Pathol, 1986, 39(1):51-57.
15. Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, Higgins JP, Rouse RV, Gokden N, McKenney JK, Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases, Am J Surg Pathol, 2011, 35(5):678-686.
16. Kwon MJ, Suh YL, Pituicytoma with unusual histological features, Pathol Int, 2011, 61(10):598-602.
17. Petersson F, Síma R, Grossmann P, Michal M, Kuroda N, Hora M, Yang X, Kinkor Z, Trivunic S, Zalud R, Sperga M, Jaunmuktane Z, Branžovský J, Ferda J, Hes O, Renal small cell oncocytoma with pseudorosettes: a histomorphologic, immunohistochemical, and molecular genetic study of 10 cases, Hum Pathol, 2011 Jun 6, doi:10.1016/j.humpath. 2011.01.022.
18. Chapman-Fredricks JR, Herrera L, Bracho J, Gomez- Fernandez C, Leveillee R, Rey L, Jorda M, Adult renal cell carcinoma with rhabdoid morphology represents a neoplastic dedifferentiation analogous to sarcomatoid carcinoma, Ann Diagn Pathol, 2011, 15(5):333-337.
19. Ansai S, Takeichi H, Arase S, Kawana S, Kimura T, Sebaceous carcinoma: an immunohistochemical reappraisal, Am J Dermatopathol, 2011, 33(6):579-587.
20. Machado I, Navarro S, López-Guerrero JA, Alberghini M, Picci P, Llombart-Bosch A, Epithelial marker expression does not rule out a diagnosis of Ewing's sarcoma family of tumours, Virchows Arch, 2011, 459(4):409-414.
21. Doyle LA, Fletcher CD, EMA positivity in epithelioid fibrous histiocytoma: a potential diagnostic pitfall, J Cutan Pathol, 2011, 38(9):697-703.
22. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T, Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immuno- cytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations, Diagn Cytopathol, 2011, 39(6):395-401.
23. Fujita K, Denda K, Yamamoto M, Matsumoto T, Fujime M, Irimura T, Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients, Br J Cancer, 1999, 80(1-2):301-308.
24. Abd Elazeez TA, El-Balshy AEM, Khalil MM, El-Tabye MM, Abdul-Halim H, Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder, Urol Ann, 2011, 3(1):8-13.
25. Lillehoj EP, Lu W, Kiser T, Goldblum SE, Kim KC, MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism, Biochim Biophys Acta, 2007, 1773(7):1028-1038.
26. Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA, Intracellular MUC1 peptides inhibit cancer progression, Clin Cancer Res, 2009, 15(1):100-109.
27. Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S, Kufe D, MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8, Cancer Res, 2008, 68(15):6136-6144.
28. Heuser C, Ganser M, Hombach A, Brand H, Denton G, Hanisch FG, Abken H, An anti-MUC1-antibody-interleukin- 2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells, Br J Cancer, 2003, 89(6):1130-1139.
29. Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, Martin AL, Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adeno-carcinoma cells, Mol Cancer Ther, 2011 Aug 23, doi:10. 1158/1535-7163.MCT-11-0381.
30. Li Y, Yi H, Yao Y, Liao X, Xie Y, Yang J, Yan Z, Wang L, Lu S, Kuang Y, Gu M, Fei J, Wang Z, Huang L, The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin, PLoS One, 2011, 6(4):e19102.
31. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D, Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells, Mol Cancer Ther, 2011, 10(5):806-816.
32. Ye Q, Yan Z, Liao X, Li Y, Yang J, Sun J, Kawano T, Wang X, Cao Z, Wang Z, Huang L, MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13, Lab Invest, 2011, 91(5):778-787.
33. Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH, Seo HS, Kim CW, Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway, Oncogene, 2011 Sep 19, doi:10.1038/onc.2011.410.
34. Yin L, Wu Z, Avigan D, Rosenblatt J, Stone R, Kharbanda S, Kufe D, MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelo- genous leukemia cells, Blood, 2011, 117(18):4863-4870.
35. Zanetti JS, Soave DF, Oliveira-Costa JP, da Silveira GG, Ramalho LN, Garcia SB, Zucoloto S, Ribeiro-Silva A, The role of tumor hypoxia in MUC1-positive breast carcinomas, Virchows Arch, 2011, 459(4):367-375.
36. Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C, Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease, J Exp Clin Cancer Res, 2009, Oct 7, 28:134.